| 000 -LEADER |
|---|
| fixed length control field |
01724pab a2200241 454500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
150901b2005 xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Tata Memorial Hospital |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
English |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
|
| Item number |
|
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Dobrowsky W |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Ak-2123 (Sanazol) as a radiation sensitizer in the treatment of stage iii cancer cervix: Initial results of an IAEA multicentre randomized trial. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc. |
2005 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
75-78 |
| 490 ## - SERIES STATEMENT |
|---|
| Series statement |
|
| Volume/sequential designation |
Vol 1 Issues 2 |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
PURPOSE : AK-2123, a nitrotriazole hypoxic cell sensitizer has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage IIIA and IIIB. MATERIALS AND METHODS : A total of 333 patients were randomised between May1995 and December1998. Patients were randomised to either standard radical treatment (radiation therapy alone, RT) or standard radical radiotherapy and additional administration of AK-2123 (RT+AK-2123). The total dose of 45-50.8 Gy was delivered in 20 to 28 fractions over 4 to 5 1/2 weeks. The dose to the central disease was escalated to a radiobiologically equivalent dose of 70 Gy by external beam or brachytherapy, in accordance with each centres individual practice. In the study arm, patients received 0.6 g/sqm AK-2123 by intravenous administra |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
RCT, cervix cancer, India,, |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
|
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Jayatilake, R S |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Huigol, N G |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
|
| 773 ## - HOST ITEM ENTRY |
|---|
| Host Biblionumber |
78381 |
| Main entry heading |
Journal of Cancer Research and Therapeutics |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| a |
Apr-Jun |
